Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) posted its earnings results on Monday. The company reported ($1.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.24) by ($0.08), MarketWatch Earnings reports. Axsome Therapeutics had a negative net margin of 101.07% and a negative return on equity of 92.39%. The firm had […]
Baldwin Brothers LLC MA lifted its position in Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) by 1.1% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 47,995 shares of the company’s stock after acquiring an additional 500 shares during the quarter. […]
Axsome Therapeutics, Inc. (NASDAQ:AXSM – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the twelve analysts that are covering the firm, Marketbeat Ratings reports. Two analysts have rated the stock with a hold rating and ten have given a buy rating to the company. The average 1 year target price among […]
Mizuho reaffirmed their buy rating on shares of Axsome Therapeutics (NASDAQ:AXSM – Free Report) in a report released on Monday morning, Benzinga reports. The brokerage currently has a $100.00 price target on the stock. Several other equities research analysts have also commented on AXSM. William Blair reiterated an outperform rating on shares of Axsome Therapeutics […]